Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Grows Position in Edwards Lifesciences Co. (NYSE:EW)

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA boosted its stake in shares of Edwards Lifesciences Co. (NYSE:EWGet Rating) by 0.2% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 964,943 shares of the medical research company’s stock after purchasing an additional 2,140 shares during the period. Edwards Lifesciences makes up about 1.2% of Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s portfolio, making the stock its 29th biggest position. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA owned approximately 0.16% of Edwards Lifesciences worth $113,593,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in EW. American National Bank boosted its holdings in shares of Edwards Lifesciences by 99.1% in the 1st quarter. American National Bank now owns 233 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 116 shares during the last quarter. EverSource Wealth Advisors LLC purchased a new stake in shares of Edwards Lifesciences in the 4th quarter valued at $29,000. Rinkey Investments purchased a new stake in shares of Edwards Lifesciences in the 4th quarter valued at $29,000. Northwest Investment Counselors LLC purchased a new stake in shares of Edwards Lifesciences in the 4th quarter valued at $30,000. Finally, Arlington Partners LLC purchased a new stake in shares of Edwards Lifesciences in the 4th quarter valued at $34,000. 82.54% of the stock is currently owned by institutional investors.

EW has been the subject of several analyst reports. StockNews.com cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Thursday, May 5th. Truist Financial initiated coverage on shares of Edwards Lifesciences in a research note on Tuesday, April 12th. They issued a “buy” rating and a $145.00 target price for the company. William Blair reiterated an “outperform” rating on shares of Edwards Lifesciences in a research note on Tuesday, April 26th. Canaccord Genuity Group decreased their target price on shares of Edwards Lifesciences from $152.00 to $137.00 in a research note on Wednesday, April 27th. Finally, Citigroup decreased their target price on shares of Edwards Lifesciences from $134.00 to $115.00 and set a “buy” rating for the company in a research note on Tuesday, May 17th. Four equities research analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $128.86.

In other news, CEO Michael A. Mussallem sold 32,550 shares of the stock in a transaction dated Friday, April 29th. The shares were sold at an average price of $107.80, for a total transaction of $3,508,890.00. Following the sale, the chief executive officer now owns 91,772 shares of the company’s stock, valued at $9,893,021.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael A. Mussallem sold 19,875 shares of the stock in a transaction dated Tuesday, June 14th. The stock was sold at an average price of $86.96, for a total transaction of $1,728,330.00. Following the sale, the chief executive officer now directly owns 157,353 shares in the company, valued at approximately $13,683,416.88. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 204,165 shares of company stock valued at $21,328,796. 1.29% of the stock is currently owned by insiders.

Shares of EW traded up $1.97 during mid-day trading on Thursday, reaching $92.76. The stock had a trading volume of 12,196 shares, compared to its average volume of 2,527,535. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.41 and a quick ratio of 2.64. Edwards Lifesciences Co. has a 52-week low of $85.58 and a 52-week high of $131.73. The business’s fifty day moving average is $101.17 and its 200 day moving average is $110.52. The firm has a market cap of $57.67 billion, a price-to-earnings ratio of 37.21, a P/E/G ratio of 2.51 and a beta of 1.17.

Edwards Lifesciences (NYSE:EWGet Rating) last announced its earnings results on Tuesday, April 26th. The medical research company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.02. The company had revenue of $1.34 billion during the quarter, compared to analyst estimates of $1.31 billion. Edwards Lifesciences had a net margin of 28.72% and a return on equity of 25.80%. Edwards Lifesciences’s revenue was up 10.2% compared to the same quarter last year. During the same quarter last year, the firm posted $0.54 earnings per share. As a group, sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.57 EPS for the current fiscal year.

Edwards Lifesciences Profile (Get Rating)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

Featured Articles

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.